Kosuke Miyai

Dr. Kosuke Miyai

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2018 in Pathology International
Verified
Journal Article
Closed access
PDF file
KMKosuke Miyai
Kosuke Miyai
HTHiroaki Takeo
Hiroaki Takeo
TNTakefumi Nakayama
Takefumi Nakayama
KOKiyohaya Obara
Kiyohaya Obara
SAShinsuke Aida
Shinsuke Aida
SMSusumu Matsukuma
Susumu Matsukuma

1 October 2019 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
KMKosuke Miyai
Kosuke Miyai
AMAyako Mikoshi
Ayako Mikoshi
FHFumiko Hamabe
Fumiko Hamabe
KNKuniaki Nakanishi
Kuniaki Nakanishi
KIKeiichi Ito
Keiichi Ito
HSHiroshi Shinmoto
Hiroshi Shinmoto

14 January 2014 in BMC Clinical Pathology
Verified
Journal Article
Open access
PDF file
SHShinsuke Hamada
Shinsuke Hamada
Akio HoriguchiAkio Horiguchi
Akio Horiguchi
KKKenji Kuroda
Kenji Kuroda
KIKeiichi Ito
Keiichi Ito
TATomohiko Asano
Tomohiko Asano
KIKeiichi Iwaya
Keiichi Iwaya
Fatty acid synthase (FAS) is highly expressed in various types of cancer, and elevated expression of FAS has been suggested to be a predictor of tumor aggressiveness and poor prognosis. We examined whether FAS expression in prostate biopsy cores could predict the pathological characteristics of radical prostatectomy (RP) specimens.

5 June 2025 in American Journal of Surgical Pathology
Verified
Journal Article
Open access
Henning ReisHenning Reis
Henning Reis
HAHikmat A. Al-Ahmadie
Hikmat A. Al-Ahmadie
NGNadine Gaisa
Nadine Gaisa
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
FMFiona Maclean
Fiona Maclean
TLThe Isup Expert Panel On Urachal Neoplasms And Urinary Bladder Glandular Lesions
The Isup Expert Panel On Urachal Neoplasms And Urinary Bladder Glandular Lesions
This manuscript summarizes the first part of the proceedings of the 2023 Dublin ISUP Consensus Conference encompassing the best practice recommendations on the pathology of neoplasms of urachal origin. The rationale for convening this consensus conference was the lack of structured and consented histopathologic recommendations in these rare tumors. Consensus among the meeting participants (n=80) was reached on the following statements: (1) combination of gross, histologic, clinical and imaging findings with exclusion of secondary tumor metastasis are to be used in the diagnosis of urachal carcinoma; (2) the 2022 World Health Organization (WHO) separate criteria for the diagnosis of urachal adenocarcinoma and for nonglandular carcinoma should be applied; (3) specific elements are to be evaluated and recorded in the gross examination of resection specimens containing urachal tumors; (4) sampling considerations for resection specimens containing urachal tumors are advised; (5) participants are against using 5% or 10% cutoff for the extent of intraepithelial carcinoma in urachal mucinous cystic tumor of low malignant potential; (6) use of immunohistochemical markers for the differential diagnosis of urachal adenocarcinomas in transurethral resection (TUR) specimen is considered optional; (7) similar tumor classificatory (nosology) rules for carcinomas arising from bladder mucosa (eg, urothelial carcinoma, squamous cell carcinoma, and neuroendocrine carcinoma) should be applied for nonglandular urachal carcinomas; (8) a new staging approach other than the previously proposed systems should be designed for urachal carcinoma; (9) a system modifying the current Tumor-Node-Metastasis (TNM)/American Joint Committee on Cancer (AJCC) staging system for urinary bladder cancer is considered appropriate for a study in urachal carcinoma; and (10) several histologic elements are to be reported when diagnosing urachal carcinoma in TUR and resection specimens. This report from the Dublin ISUP consensus conference will serve as a practice recommendation for pathologists and as a guide for future standardized reporting protocols and research regarding urachal tumors. In addition, an international database for urachal cancers under the guidance of ISUP is being planned to be established to address pertinent issues in the pathology of urachal cancers.

6 January 2021 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
KKKazuki Kawamura
Kazuki Kawamura
KMKosuke Miyai
Kosuke Miyai
JAJunichi Asakuma
Junichi Asakuma
KSKimiya Sato
Kimiya Sato
SMSusumu Matsukuma
Susumu Matsukuma
KIKeiichi Ito
Keiichi Ito

18 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKosuke Miyai
Kosuke Miyai
KKKazuki Kawamura
Kazuki Kawamura
KIKeiichi Ito
Keiichi Ito
SMSusumu Matsukuma
Susumu Matsukuma
HTHitoshi Tsuda
Hitoshi Tsuda
Periostin is an extracellular matrix protein that has been known to be implicated in fibrillogenesis and cell migration, including cancer metastasis. Periostin overexpression in cancer cells and/or intervening stroma is usually related to tumor progression and poor patient outcomes in various human cancers; however, its role in urothelial carcinoma, especially upper urinary tract urothelial carcinomas (UTUCs), remains inconclusive. Samples from 126 consecutive cases of invasive UTUC (69 renal pelvic cancers and 57 ureteral cancers) were histologically reviewed and analyzed for periostin expression using immunohistochemistry. The intensities of immunoreactivity and the fraction of positive cancer cells and stroma (i.e., epithelial and stromal expression, respectively) were classified into four categories each (intensity, 0–3; fraction, 0–25% = 1; 26–50% = 2; 51–75% = 3; and > 75% = 4). The overall score was determined by multiplying both scores, and overall scores ≥ 6 were considered to indicate high periostin expression. Among 126 UTUCs, 55 (44%; 27 renal pelvic and 28 ureteral cancers) showed high stromal periostin expression. None of the cases were considered to have high epithelial periostin expression. High stromal periostin expression was associated with non-papillary gross findings, higher pathological T category, lymphovascular invasion, concomitant carcinoma in situ, subtype histology, lymph node metastasis, positive surgical margins, high tumor budding, and high tumor-associated immune cell status. Multivariate analysis revealed that high stromal periostin expression was an independent predictor of overall survival (p = 0.00072, hazard ratio = 3.62), and lymphovascular invasion and high stromal periostin expression were independent predictors of cancer-specific survival (p = 0.032 and 0.020, hazard ratio = 2.61 and 3.07, respectively). Stromal periostin expression was often observed in invasive UTUCs with adverse clinicopathological factors and may be a useful predictor of patient outcomes.